ClinicalTrials.gg
TerminatedNCT04325698Updated Oct 1, 2024Results posted

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

A Phase 3 interventional study of PF-06439535 (CN) and Bevacizumab-EU in Advanced Non-squamous NSCLC, sponsored by Pfizer. Terminated at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizumab sourced from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.

02

Conditions studied

  • Advanced Non-squamous NSCLC
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants age at least 18 years of age.
  • Newly diagnosed Stage IIIB, IIIC or IV non small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer (AJCC) Staging Manual, 8th Edition, last updated 05 June 2018) or recurrent NSCLC.
  • or cytologically confirmed diagnosis of non-squamous NSCLC.
  • At least one as defined by v1.1.
  • Be eligible to receive bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or non-squamous NSCLC.

Exclusion criteria

Exclusion Criteria:

  • Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas.
  • Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that, in the opinion of the investigator, is likely to bleed.
  • Known EGFR activating mutations (for example, exon 19 deletion or exon 21 L858R substitution mutations) or ALK rearrangements.
  • Prior systemic therapy for advanced NSCLC; prior or adjuvant therapy is allowed if surgical resection for primary disease was performed.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Arm A

    PF-06439535 (CN) + paclitaxel + carboplatin

    Drug: PF-06439535 (CN) · Drug: Paclitaxel · Drug: Carboplatin

  • Active comparator
    Arm B

    Bevacizumab-EU + paclitaxel + carboplatin

    Drug: Bevacizumab-EU · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • 15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.

  • 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study

    Also known as: Avastin

  • 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

  • AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Objective Response

    Objective response referred to complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (non-progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions, normal nodes (target nodes must decrease to normal size); PR: \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.

    Time frame: From Week 1 to Week 25 (25 Weeks)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Treatment Period

    TEAE was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event (AE) that worsens after the beginning of the investigational product. Serious adverse events (SAE) were assessed by the investigator. Severity of AE was graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.

    Time frame: From Day 1 to end of Cycle 8; 1 Cycle = 21 Days

  2. Number of Participants With Anti-Drug Antibodies (ADA)

    ADA have been evaluated in studies with bevacizumab in cancer patient populations. A sensitive and specific immunoassay for detecting ADA in human serum was used to analyze the ADA samples (blood samples for assessment of ADA collected at specified timepoints).

    Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days

  3. Number of Participants With NAb

    Blood samples for assessment of ADA and NAb were collected at specified time point. Samples that were determined positive for ADA were further characterized for NAb using a single validated NAb assay.

    Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days

  4. Trough and Apparent Peak PF-06439535 (CN) and Bevacizumab (EU) Concentrations

    The drug concentrations were determined using serum samples collected at the time points specified.

    Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 2.5 hours after initiation of bevacizumab infusion on Day 1 of Cycle 1 and Cycle 5; 1 Cycle = 21 Days

  5. Number of Participants With TEAEs in Extension Period

    Treatment emergent adverse event (TEAE) was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event that worsens after the beginning of the investigational product. Serious adverse events were assessed by the investigator. Severity of AE was graded based on NCI CTCAE version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.

    Time frame: Cycle 9 Day 1 up to End of Treatment (up to Cycle 14 Day 21); 1 Cycle = 21 Days

07

Results

Posted Oct 1, 2024
Limitations and caveats
The study was terminated on 17 March 2021 by the Sponsor. The decision to terminate this study was based on a business review of the biosimilars market and the Sponsor's global manufacturing network. This decision was not based on any safety or regulatory concerns with the treatment of participants with PF-06439535 (CN). The results reported are limited to safety, PK and immunogenicity, and only safety is summarized.

Participant flow

The study was terminated on 17 March 2021 by the Sponsor. This study was conducted in China.

Participant flow — Overall Study
MilestonePF-06439535 (CN)Bevacizumab (EU)
Started44
Completed31
Not completed13
Withdrew: Study terminated by sponsor11
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryPercentage of Participants Achieving Objective Response

Objective response referred to complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (non-progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions, normal nodes (target nodes must decrease to normal size); PR: \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.

Time frame:
From Week 1 to Week 25 (25 Weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) in Treatment Period

TEAE was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event (AE) that worsens after the beginning of the investigational product. Serious adverse events (SAE) were assessed by the investigator. Severity of AE was graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.

Time frame:
From Day 1 to end of Cycle 8; 1 Cycle = 21 Days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Treatment Period
ParticipantsPF-06439535 (CN)Bevacizumab (EU)
Participants with all causalities AEs44
Participants with all causalities SAEs12
Participants with all causalities AEs of maximum grade 3 or 423
Participants with all causalities AEs of maximum grade 500
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs44
Participants with PF-06439535 (CN) or bevacizumab (EU)-related SAEs01
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 3 or 412
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 500
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA)

ADA have been evaluated in studies with bevacizumab in cancer patient populations. A sensitive and specific immunoassay for detecting ADA in human serum was used to analyze the ADA samples (blood samples for assessment of ADA collected at specified timepoints).

Time frame:
Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA)
ParticipantsPF-06439535 (CN)Bevacizumab (EU)
Cycle 1_Day 1_ADA Positive00
Cycle 5_Day 1_ADA Positive00
End of Treatment Positive00
SecondaryNumber of Participants With NAb

Blood samples for assessment of ADA and NAb were collected at specified time point. Samples that were determined positive for ADA were further characterized for NAb using a single validated NAb assay.

Time frame:
Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days

No measurements were reported for this outcome.

SecondaryTrough and Apparent Peak PF-06439535 (CN) and Bevacizumab (EU) Concentrations

The drug concentrations were determined using serum samples collected at the time points specified.

Time frame:
Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 2.5 hours after initiation of bevacizumab infusion on Day 1 of Cycle 1 and Cycle 5; 1 Cycle = 21 Days

No measurements were reported for this outcome.

SecondaryNumber of Participants With TEAEs in Extension Period

Treatment emergent adverse event (TEAE) was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event that worsens after the beginning of the investigational product. Serious adverse events were assessed by the investigator. Severity of AE was graded based on NCI CTCAE version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.

Time frame:
Cycle 9 Day 1 up to End of Treatment (up to Cycle 14 Day 21); 1 Cycle = 21 Days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs in Extension Period
ParticipantsExtension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN)
Participants with all causality AEs3
Participants with all causality SAEs1
Participants with all causality AEs of maximum grade 3 or 41
Participants with all causality AEs of maximum grade 50
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs2
Participants with PF-06439535 (CN) or bevacizumab (EU)-related SAEs0
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 3 or 41
Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 50

Adverse events

Collected over From ICD through and up to 28 days after last dose of investigational product or prior to the start of new anticancer therapy, whichever occurred first (up to 311 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: PF-06439535 (CN)0/4 (0%)1/4 (25%)4/4 (100%)
Treatment Period: Bevacizumab (EU)0/4 (0%)2/4 (50%)4/4 (100%)
Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN)0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment Period: PF-06439535 (CN)Treatment Period: Bevacizumab (EU)Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN)
NeutropeniaBlood and lymphatic system disorders1/42/40/3
PneumoniaInfections and infestations1/40/41/3
PyrexiaGeneral disorders0/41/40/3
Most frequent other events
Showing 10 of 58
Most frequent other events
EventTreatment Period: PF-06439535 (CN)Treatment Period: Bevacizumab (EU)Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN)
HyponatraemiaMetabolism and nutrition disorders4/40/42/3
AnaemiaBlood and lymphatic system disorders3/41/42/3
Neutrophil count decreasedInvestigations1/43/41/3
White blood cell count decreasedInvestigations3/43/41/3
AlopeciaSkin and subcutaneous tissue disorders2/43/40/3
HypoalbuminaemiaMetabolism and nutrition disorders1/41/42/3
ProteinuriaRenal and urinary disorders1/41/42/3
VertigoEar and labyrinth disorders2/40/40/3
DiarrhoeaGastrointestinal disorders1/42/40/3
NauseaGastrointestinal disorders2/42/41/3

Baseline characteristics

Age, Customized
Age, Customized(Participants)PF-06439535 (CN)Bevacizumab (EU)Total
NumberNANANA
Sex: Female, Male
Sex: Female, Male(Participants)PF-06439535 (CN)Bevacizumab (EU)Total
FemaleNANANA
MaleNANANA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06439535 (CN)Bevacizumab (EU)Total
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Dongguan People's Hospital
    Dongguan, Guangdong 523059, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in May 2021, 10 months.

Results were first posted in Oct 2024, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Mar 27, 2020
StartActual
Jun 11, 2020
Primary completionActual
May 10, 2021
CompletionActual
May 10, 2021
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04325698
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 27, 2020
Start date
Jun 11, 2020
Primary completion
May 10, 2021
Completion
May 10, 2021
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion